# US 9,040,091 B2 · Compositions and methods for oral delivery of encapsulated diethylenetriaminepentaacetate particles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,040,091 B2
- Document ID: US9040091B2
- Status: Granted
- Kind: B2
- Application number: 13/827,667
- Filed: 2013-03-14
- Published: 2013-09-26
- Granted: 2015-05-26
- Earliest claimed: 2012-03-22
- Assignees: Nanotherapeutics, Inc.
- Applicants: Nanotherapeutics, Inc.
- Inventors: James David Talton
- Web page: https://patentgrep.com/patent/US9040091B2

## CPC

- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/4891: {Coated capsules; Multilayered drug free capsule shells (with drug coating for immediate release A61K9/4808; osmotic devices A61K9/0004)}
- A61K 31/315: Zinc compounds
- A61K 33/30: Zinc; Compounds thereof
- A61P 39/00: General protective or antinoxious agents
- A61P 39/04: Chelating agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure is directed to compositions comprising encapsulated particles of diethylenetriaminepentaacetate (DTPA) and a zinc salt such as zinc acetate, and to pharmaceutical compositions comprising such encapsulated compositions. The present disclosure is also directed to methods of treatment by administering an effective amount of the compositions and pharmaceutical compositions of the present disclosure, to methods of making such encapsulated particle compositions, and to methods of making the corresponding pharmaceutical compositions.

## Claims

### Claim 1

A composition comprising particles of diethylenetriaminepentaacetate (DTPA) and a zinc salt, wherein the DTPA and the zinc salt are encapsulated by an enteric-coated polymer, and wherein the zinc salt is zinc acetate.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the particles have an average diameter of less than about 1 mm.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the particles have an average diameter of less than about 300 μm.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the particles have an average diameter of less than about 100 μm.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the DTPA is an acid.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the DTPA is a salt.

### Claim 7 (depends on 1)

The composition of claim 1, wherein zinc acetate improves solubility of DTPA by an amount greater than about 20%.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the enteric-coated polymer is a water-soluble polymer.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the enteric-coated polymer is a methacrylic acid copolymer.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the DTPA is present in an amount ranging from about 0.01% to about 90% by mass of the composition.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the DTPA is present in an amount ranging from about 10% to about 90% by mass of the composition.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the DTPA is present in an amount ranging from about 50% to about 80% by mass of the composition.

### Claim 13 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition is formulated for oral administration.